Winter 2011
Volume 2, Issue 2
Johns Hopkins Vaccine Initiative
Vaccine Day 2011: Anne Schuchat
On October 7th, 2011, the Johns Hopkins
Vaccine Initiative (JHVI) hosted the fourth
annual Vaccine Day at the Johns Hopkins
Bloomberg School of Public Health. JHVI was
pleased to host Dr. Anne Schuchat, MD
(RADM, USPHS), Assistant Surgeon General,
United States Public Health Service, Director,
National Center for Immunization and Respiratory Diseases, Centers for Disease Control
and Prevention.
Vaccine Day began at 12:00pm in Sommer
Hall with welcome by Ruth Karron, M.D.,
Director of the Johns Hopkins Vaccine Initiative and an introduction by the Dean of the
School of Public Health, Michael Klag, MD,
MPH.
Dr. Schuchat's keynote address was titled
"Magic bullets and smoking guns, flying
pigs and sitting ducks: What can we learn
from the past for the new Decade of
Vaccines?"
Following the keynote, an expert panel
moderated by Neal Halsey, M.D. discussed
issues surrounding vaccine research and
implementation.
The guest panel included former students:
JHVI
Newsletter
Winter
2011
The Johns Hopkins Vaccine
Initiative promotes collaborative
and interdisciplinary vaccine
research, education, and
implementation efforts to
improve health worldwide.
Anne Bailowitz, MD, MPH
Assistant Commissioner, Clinical Services
Baltimore City Health Department
Angelia Eick-Cost, PhD, ScM
Special Studies Lead Armed Forces
Health Surveillance Center
T. Christopher Mast, PhD, MSc
Director and Infectious Disease Area
Lead Department of Epidemiology
Merck Research Laboratories
Inside this issue:
Vaccine Day 2012
1-3
Daniel Salmon, MPH, PhD
Director, Vaccine Safety, National
Vaccine Program Office, Office of Public
Health and Science, US DHHS
WHO Collaborating Center
4
Announced at JHSPH
50th Anniversary Vaccine
Seminar
4
Following the presentation and panel discussion, Vaccine Day moved to Feinstone Hall
for the faculty, staff and student poster
session and reception. 34 posters were
submitted for Vaccine Day 2011 showcasing
work from four departments, including 18
student posters. The posters highlighted the
breadth of vaccine research being conducted
at the School, and described pre-clinical
studies, phase I and II clinical trials, cost
effectiveness studies, policy analysis, and
implementation studies. Thirteen posters
submitted were eligible for the student
poster contest.
Dr. Black Receives Award
5
World Pneumonia Day
Activities at JHSPH
5-6
Dr. O’Brien Receives
Presidential Award
6
JHVI VIEW Scholars
Internships Available
7
Anne Schuchat, MD
Assistant Surgeon General, United States Public Health Service
Director, National Center for Immunization and Respiratory
Diseases Centers for Disease Control and Prevention (CDC)
(Continued on page 2)
JHMRI Malaria Anniversary
7
and Symposium
Recent Research
Announcements
8-9
JHVI Faculty Selected
Publications
9-11
Page 2
Johns Hopkins Vaccine Initiative
Volume 2, Issue 2
Vaccine Day 2011 Poster and Photo Contest Winners
Prizes were awarded for the three most outstanding student posters:
First Place: Barbara Badman (right) "Investigating the Genotypic Distribution of
High-Risk Human Papillomavirus among Women in Northern Tanzania in an
Effort to Determine Vaccine Efficacy"
Second Place: Cailin Deal "The role of the Influenza A Virus M2 protein extracellular domain in virus replication and on the induction of broadly protective antibodies"
Third Place: Kyla Hayford "Validating measles vaccination coverage estimates
using an oral fluid biomarker: Preliminary findings from a population-based
study in rural Bangladesh"
Please see here for a list of all abstracts submitted.
2011 Vaccine Day Photo Contest
Photos submitted in advance of the Decade of Vaccines photo contest were judged by JHSPH faculty for best
illustrating the impact of vaccines on public health.
Second Place: Laveta Stewart (below)
NNIPS field staff members volunteered in
large numbers to receive their influenza
immunization.
First Place: Kyla Hayford (above) For an immunization campaign day in
Bangladesh, this volunteer loads his bike with coolers full of measles
and polio vaccines and delivers them to each community.
Third Place: Andrea Feller (left) In the Matlab research area of
ICDDR,B, the Community Health Research Worker (CHRW) holds
fixed-site clinics in her house where she administers EPI vaccines. In this photo the CHRW is preparing to administer the
vaccines to an infant. Educational posters can be seen hanging
on the walls.
Page 3
Johns Hopkins Vaccine Initiative
Vaccine Day 2011 Photos
Page 4
Volume 2, Issue 2
Johns Hopkins Vaccine Initiative
WHO Collaborating Center for Vaccine Epidemiology
and Evaluation at JHSPH
The World Health Organization has established a Collaborating Center for Vaccine Epidemiology and Evaluation
at the Johns Hopkins Bloomberg School of Public Health, Department of International Health. Faculty, students
and staff of the Bloomberg School of Public Health will work with colleagues in
the Department of Immunization, Vaccines and Biologicals at WHO and with
colleagues at PAHO on the following activities:
The Collaboration intends to:
1. Support, collaborate on, or conduct systematic analysis of vaccine-related
scientific evidence;
2. Provide technical assistance and support training on the design, conduct and
analyses of vaccine trials and evaluation in the pre- and post-licensure phases;
3. Support, collaborate on, conduct, and/or provide training to conduct epidemiological studies to develop and improve strategies for optimal safety and
effectiveness of vaccines, with an emphasis on measles and dengue viruses.
4. Build capacity for vaccine research in resource-poor settings, through training in areas such as systematic literature review and/or good clinical practice
(GCP).
“In addition to ongoing projects related to safety
assessments for dengue virus vaccines and assessment of coverage with measles vaccine, we will
be working on additional projects related to
global coverage with influenza vaccines.”
For more information, see the JHVI website.
-Dr. Ruth Karron
Director, Johns Hopkins Vaccine Initiative (JHVI)
JHSPH Department of International Health 50th Anniversary Seminar
The Institute for Vaccine Safety, the Center for Immunization Research and GDEC sponsored a 50th Anniversary
seminar on November 9th, 2011 with Gareth Williams, Chair of the Jenner Trust, Dr. Jenner’s House and Professor,
University of Bristol. The seminar, during the Special
Topics in Vaccine Science Seminar, was in support of
research Dr. Williams has completed on Edward Jenner
and the development of the smallpox vaccine, described
in his Angel of Death: the Story of Smallpox, shortlisted
for the Wellcome Book Prize 2010 (all proceeds to Dr.
Jenner’s House). Dr. Williams described the development of the smallpox vaccine and linked the anti-vaccine
movement through history to the current anti-vaccine
movement in America and the UK.
Dr. Jenner (right) with JHSPH faculty, students and Dean Sommer.
A video of the seminar is hosted on the Johns Hopkins Vaccine Initiative website here.
Page 5
Johns Hopkins Vaccine Initiative
Robert E. Black Received Prince Mahidol Award
Robert E. Black, MD, MPH, is a recipient of the Prince
Mahidol Award in the field of Public Health, which
recognizes “outstanding contribution in the field of public health for the sake of the well-being of the peoples.”
Black, who is chair and Edgar Berman Professor in
International Health at the Johns Hopkins Bloomberg
School of Public Health, is being recognized for his outstanding work on zinc supplementation. His studies in
Bangladesh, India, Peru and Zanzibar demonstrated that
daily zinc supplementation significantly reduced the
severity of diarrhea and pneumonia.
“The Prince Mahidol Award is a tremendous honor and
well-deserved recognition of Bob Black's contributions
and commitment to improve the lives of children worldwide,” said Michael J. Klag, MD, MPH, dean of the Johns
Hopkins Bloomberg School of Public Health.
The Prince Mahidol Award was established in honor of
the late Prince Mahidol of Songka, the Royal Father of
His Majesty the King of Thailand. Prince Mahidol modernized medical services and education in Thailand and
is known to the country as the “Father of Modern
Medicine and Public Health.”
Alfred Sommer, MD, MHS, professor and dean emeritus
of the Bloomberg School, received the Prince Mahidol
Award in 1997 for his vitamin A discoveries.
Black’s research interests include field trials of vaccines,
micronutrients and nutritional interventions, effectiveness studies of health programs, such as the Integrated
Management of Childhood Illness approach, and evaluation of preventive and curative health service programs
in low- and middle-income countries. He currently has
Throughout his career,
active projects in Bangladesh, Ethiopia, India, Peru,
Black has focused his
Uganda and Zanzibar. He focuses on using evidence in
research and activities on policy and programs, including estimates of burden of
reducing the unnecessary disease, the development of research capacity and the
deaths of children world- strengthening of public health training.
wide from infectious
Trained in internal medicine, preventive medicine,
diseases and malnutriinfectious diseases and epidemiology, Black has served
tion. Black shares this
as a medical epidemiologist at the Centers for Disease
year’s award with Ananda
Control and Prevention and worked at institutions in
S. Prasad of Wayne State
Bangladesh and Peru on research related to childhood
University and Kenneth H.
infectious diseases and nutritional problems. As a memBrown of the University
ber of the U.S. Institute of Medicine and advisory bodies
of California at Davis.
of the World Health Organization, the International
The $50,000 prize will be conferred on the recipients by Vaccine Institute, and other international organizations,
His Majesty the King of Thailand Bhumibol Adulyadej, at he assists with the development of policies intended to
a ceremony in Bangkok on January 26, 2011.
improve child health.
Reprinted from the JHSPH Public Health News Center
World Pneumonia Day, November 12, 2011
th
November 12 marked the third annual celebration of World Pneumonia Day (WPD).
Pneumonia is the world’s leading killer of children under five. It takes the life of one
child every 20 seconds – that’s more than AIDS, measles and malaria combined. WPD
puts a spotlight on the problem of childhood pneumonia for the world’s stage.
In just three years, WPD has truly become a global phenomenon with dozens of events
occurring in over 20 countries this year. International Vaccine Access Center (IVAC)
supported the efforts of the Global Coalition against Child Pneumonia and helped to lead
a successful digital campaign, which resulted in the production of fantastic resources like
the WPD video and infographic.
(Continued on page 6)
Page 6
Johns Hopkins Vaccine Initiative
Volume 2, Issue 2
World Pneumonia Day (continued)
IVAC also coordinated the 2011 Small Grants for World
Pneumonia Day Advocacy Program which, through partnerships with the GAVI Alliance, the Best Shot Foundation and the Global Alliance for Clean Cookstoves,
provided support for passionate advocates to hold
events on WPD where childhood pneumonia has the
greatest impact.
Epidemiology, Dr. Daniel Feikin, M.D. appeared on an
ABC News segment with Dr. Richard Besser and contributed a blog about the impact pneumococcal conjugate
vaccine (PCV) introduction in Kenya, where he had
worked previously.
Just prior to WPD, IVAC published the 2011 Pneumonia
Progress Report. The annual report examines data on
several key pneumonia interventions – including exclusive breastfeeding, access to a health care facility, antibiotic treatment and vaccination against pneumonia’s four
leading causes – in the 15 countries that account for
three-fourths of all child pneumonia deaths.
An animated version of the Progress Report can be
viewed here.
IVAC faculty and staff were also vital in spreading awareness about childhood pneumonia on and around World
Pneumonia Day through participation in blogger calls,
blog pieces and media interviews. Dr. Katherine O’Brien,
M.D. contributed a blog about her own personal
experience with pneumonia that was published on the
Coalition website and Results UK. IVAC’s Director of
Lois Privor-Dumm, IVAC’s
Director of Alliances and
Information, wrote a blog
for Disruptive Women in
Health Care about the
creativity of WPD events
and outreach. Executive
Director of IVAC, Dr. Orin
Levine debunked the Top
5 Pneumonia Myths in a
Huffington Post blog and
contributed to a PBS News
Hour report by Ray Suarez,
which provided an update
on pneumonia prevention
in Nicaragua a year after
they rolled-out PCV,
through an interview.
JHSPH Students/Pneumonia Fighters
in front of Welch Library
Katherine O’Brien Receives Receive Presidential Early Career Award
October 14, 2011 at the Museum of Natural History in Washi ngton, DC.
Dr. Katherine O’Brien, M.D., M.P.H., was among 94 researchers honored by President Obama in October as they received the Presidential Early Career Awards for Scientists and Engineers, the highest honor bestowed by the United
States government on science and engineering professionals in
the early stages of their independent research careers.
O’Brien is a pediatric infectious disease physician, an epidemiologist and a vaccinologist with the Bloomberg School’s
departments of International Health and Epidemiology. She
leads the Infectious Disease Prevention group in the School’s
Center for American Indian Health, where she conducts clinical
trials of vaccines for diseases of importance to American
Indian tribes.
From left to right: Francis Collins (NIH Director), Kathleen Sebelius
(Secretary of Department of Health and Human Services), Katherine O’Brien, and John Holdren (Assistant to the President, White
House Office of Science and Technology)
She also serves as deputy director of the International Vaccine
Access Center (IVAC). Her work domestically and internationally has focused on vaccine-preventable childhood illnesses
including epidemiologic and vaccine studies of pneumococcal
disease, rotavirus, Haemophilus influenzae, respiratory
syncytial virus and influenza.
Page 7
Johns Hopkins Vaccine Initiative
Vaccine Internship Experience at WHO (VIEW) Fall 2012 Internships in Geneva
The Johns Hopkins Vaccine Initiative 2012-2013 Vaccine
Internship Experience at WHO (VIEW) internship descriptions and applications are now available.
The VIEW Scholars Program is funded by the Johns
Hopkins Vaccine Initiative. The objective of the VIEW
Scholars Program is to allow JHSPH graduate students to
work with mentors in the Department of Immunization,
Vaccines and Biologicals at the World Health Organization
(WHO) to gain experience in vaccine research, policy, or
programs of global importance.
minimum of three terms of biostatistics and one term of
epidemiology.
Applicants must anticipate enrollment as full time
students during their internships (the first and second
quarters of the 2012-2013 academic year).
JHVI and WHO will arrange internships on vaccine-related
topics of global importance that will provide opportunities
for students to apply skills acquired at JHSPH. However, it
is essential that WHO has the flexibility to adjust internships to respond to critical or emerging public health
Specific projects will vary, but might include analytic work needs. Following the identification of VIEW Scholars, JHVI
or specific assignments that contribute to the developand WHO will assign internships based on student interest
ment of global immunization policy recommendations, the and experience and WHO programmatic needs.
strengthening of national decision making processes for
All applications and recommendations are due Friday
immunization, vaccine delivery, financing, or safety
January 27, 2012 at 5:00pm. Contact Amber Bickford Cox
monitoring, or vaccine preventable disease surveillance.
with questions [email protected] or [email protected]
Three internships will be offered during the 2012-2013
academic year. VIEW Scholars will receive $7,500 to be
used for travel, accommodation and expenses while in
Geneva. The VIEW Scholars Program is restricted to fulltime master’s and doctoral students in good standing
enrolled at the Johns Hopkins Bloomberg School of Public
Health. As this internship is intended to complement
course work taken at the School of Public Health, all
applicants are required to have completed at least one
year of coursework by September 2012, including a
Johns Hopkins Malaria Research Institute
On November 16, the Johns Hopkins Bloomberg School of Public Health hosted “The Forever War: Malaria versus The
World,” a half-day symposium calling attention to the global burden imposed by malaria. The event, held at the New
York Academy of Science in New York City, also marked the tenth anniversary of the Johns Hopkins Malaria Research
Institute, a state-of-the-art research facility at the Bloomberg School of Public Health focused on a broad program of
basic science research to treat and control malaria. Worldwide, malaria afflicts
hundreds of millions of people.
The symposium highlighted some of the groundbreaking research conducted
by the Johns Hopkins Malaria Research Institute and other scientists working
to end malaria. Nobel Laureate Peter Agre, director of the Johns Hopkins
Malaria Research Institute, moderated the presentation, which included discussions of interventions in Macha, Zambia that have reduced malaria locally
by 90 percent, the development of a genetically modified malaria-resistant
mosquito, and understanding of genetics of the parasite that causes malaria.
Michael J. Klag, (far left), joins Diane E. Griffin, the
The Honorable Michael Bloomberg provided the symposium’s opening adHonorable Michael Bloomberg, Peter C. Agre and
dress. Jeffrey D. Sachs, director of the Earth Institute and professor at Colum- Alfred Sommer for the symposium.
bia University, provided the closing keynote address. Michael J. Klag, dean of
the Bloomberg School, and Ellis Rubinstein, head of the New York Academy, also delivered remarks.
More info at JHMRI.
Page 8
Johns Hopkins Vaccine Initiative
Volume 2, Issue 2
Researchers Develop Method to Better Estimate Vaccine Coverage
Immunizations are a valuable tool for controlling infectious
diseases among populations both in the U.S. and globally.
Routine immunizations and supplemental immunization
activities, such as immunization campaigns, are designed
to provide immunization coverage to entire populations.
Current measurements used to determine the success and
rates of immunization can be flawed and inconsistent. According to a new study led by researchers from the Johns
Hopkins Bloomberg School of Public Health, estimates of
vaccination coverage can be significantly improved by
combining administrative data with survey data. The results are featured in the Oct 2011 issue of PLoS Medicine.
method was applied using demographic health survey and
administrative coverage data reported to the WHO from
measles vaccinations in Ghana, Madagascar and Sierra
Leone. They found estimates of routine supplemental immunization activities coverage are substantially lower than
administrative estimates for Madagascar and Sierra Leone,
and only slightly lower for Ghana. In addition, their estimates of routine coverage are, in general, lower than
WHO and United Nations Children’s Fund (UNICEF) estimates.
“This method not only attempts to correct coverage estimates, but also distinguishes between issues of overall
“Reliable estimates of vaccination coverage are key to
coverage and vaccine within activity inefficiencies. For our
managing population immunization status,” said Justin
technique to be useful, countries must have crossLessler, lead author of the study and an assistant professor sectional data on vaccine coverage for children across a
with the Bloomberg School’s Department of Epidemiology. range of ages, some of an age where they have been ex“Currently, the performance of routine and supplemental posed to multiple vaccination activities,” said Derek Cumimmunization activities is measured by the administrative mings.
method, which leads to coverage estimates that are often
“Estimates of the inefficiency of past vaccination activities
inconsistent with the proportion reporting vaccination in
and the proportion not covered by any activity allow us to
cross-sectional surveys. Furthermore, administrative covmore accurately predict the results of future activities and
erage does not tell you how many people are systematiprovide insight into the ways in which vaccination procally missed by vaccination activities. We estimated that
grams are failing to meet their goals,” adds Lessler.
the size of the population never reached by any activity
was high in Sierra Leone and Madagascar, 31 percent and “Measuring the Performance of Vaccination Programs Using Cross-Sectional Surveys: A Likelihood Framework and
21percent respectively. But it was much lower in Ghana,
Retrospective Analysis” was written by Justin Lessler, C.
only 7 percent. ”
Jessica E. Metcalf, Rebecca F. Grais, Francisco J. Luquero,
The widely used administrative method divides the numDerek A. T. Cummings and Bryan T. Grenfell.
ber of doses distributed by the size of the target populaThis research was supported by grants from the Vaccine
tion. Lessler, along with colleagues from Johns Hopkins,
Modeling Initiative of the Bill and Melinda Gates FoundaUniversity of Oxford, Epicentre, and Princeton University
developed a method for estimating the effective coverage tion, the Department for Homeland Security, the NIH, the
Burroughs Welcome Fund and the Royal Society.
of vaccination programs using cross-sectional surveys of
vaccine coverage combined with administrative data. The Reprinted from the JHSPH Public Health News Center
Center for Immunization Research, PATH and NIH Evaluate New Malaria Vaccine
The Johns Hopkins Bloomberg School of Public Health Center for Immunization Research (CIR), the PATH Malaria
Vaccine Initiative (MVI) and the National Institute of Allergy and Infectious Diseases (NIAID) announced a new
collaboration to evaluate a potential malaria vaccine
designed to prevent transmission of the disease from
mosquitoes to humans.
transmission of malaria from mosquitoes to humans by
preventing the malaria parasite from developing in the
mosquito. While such vaccines do not directly protect an
immunized individual from developing clinical malaria, by
preventing the spread of infection by the mosquito, they
can reduce the chances that others in the community
contract the disease.
CIR, MVI and NIAID are currently working together to con- "The Pfs25 vaccine and other transmission-blocking vacduct a Phase 1 clinical trial in healthy adults to assess the cines are unique in their approach in that they target a key
safety and immunogenicity of the protein Pfs25. Pfs25 is a
(Continued on page 9)
transmission-blocking vaccine (TBV) that aims to block the
Page 9
Johns Hopkins Vaccine Initiative
(Continued from Page 8 Malaria Vaccine) stage in the
malaria parasite's lifecycle rather than attempting to build
immunity to malaria in humans," said Kawsar Talaat, MD,
clinical principal investigator and assistant scientist at the
Johns Hopkins Bloomberg School of Public Health. "We'll
need many tools to bring malaria under control and an
effective transmission-blocking vaccine could go a long
way toward achieving that goal."
Malaria kills nearly 800,000 people every year, most of
them children under the age of 5. Defending against the
disease has been challenging because both the parasite
and its mosquito host are highly adaptive and have survived for millions of years. A TBV would work synergistically with other interventions such as drugs and insecticides since blocking transmission of the parasite would
reduce the pressure on these measures, thereby slowing
the development of resistance and thus extending their
effectiveness.
grant from the Bill & Melinda Gates Foundation. MVI’s
mission is to accelerate the development of malaria vaccines and ensure their availability and accessibility in the
developing world. MVI’s vision is a world free from malaria. For more information, please visit http://
www.malariavaccine.org/.
About PATH: PATH is an international nonprofit organization that creates sustainable, culturally relevant solutions,
enabling communities worldwide to break longstanding
cycles of poor health. By collaborating with diverse public
and private sector partners, PATH helps provide appropriate health technologies and vital strategies that change
the way people think and act. PATH’s work improves
global health and well-being. For more information, please
visit http://www.path.org/.
About the Johns Hopkins Center for Immunization Research
(CIR): CIR is a leader in vaccine evaluation and Good Clinical Practice (GCP) training. Established in 1985 by Dr. Mary
"This is the first clinical trial using a transmission-blocking Lou Clements-Mann, CIR is one of the nation’s leading vacapproach supported by MVI," said Ashley Birkett, director cine research centers. CIR investigators primarily conduct
of research and development at MVI. “It’s the first step in Phase I and II clinical trials of new vaccine candidates in
what is typically a long process of evaluation. Nonetheless, the United States and in less-developed countries.
we are excited by the potential of TBVs to significantly
About the National Institute of Allergy and Infectious Dislimit the spread of malaria infection. Eradication of malaria
eases (NIAID): NIAID conducts and supports research—at
may be decades away, but we believe a successful TBV—
NIH, throughout the United States, and worldwide—to
used alongside safe and effective drugs, insecticides,
study the causes of infectious and immune-mediated disbednets and possibly a malaria vaccine that protects the
eases, and to develop better means of preventing, diagindividual against infection—is essential to achieving that
nosing and treating these illnesses. News releases, fact
goal.”
sheets and other NIAID-related materials are available on
About the PATH Malaria Vaccine Initiative (MVI): MVI is a the NIAID website at http://www.niaid.nih.gov/.
global program established at PATH through an initial
Selected Faculty Publications and Faculty in the News
BCG-mediated protection against Mycobacterium ulcerans infection in the mouse.
Converse PJ, Almeida DV, Nuermberger EL, Grosset JH.
PLoS Negl Trop Dis. 2011 Mar 15;5(3):e985. PMID: 21423646
Comparison of LiST measles mortality model and WHO/IVB measles model.
Chen WJ. BMC Public Health. 2011 Apr 13;11 Suppl 3:S33.
PMID: 21501452
Scaling up diarrhea prevention and treatment interventions: a
Lives Saved Tool analysis.
Fischer Walker CL, Friberg IK, Binkin N, Young M, Walker N,
Fontaine O, Weissman E, Gupta A, Black RE. PLoS Med. 2011
Mar;8(3):e1000428. Epub 2011 Mar 22. PMID: 21445330
Rotavirus vaccine and diarrhea mortality: quantifying regional
variation in effect size.
Fischer Walker CL, Black RE. BMC Public Health. 2011 Apr 13;11
Suppl 3:S16. Review. PMID: 21501433
An open label Phase I trial of a live attenuated H6N1 influenza
virus vaccine in healthy adults.
Talaat KR, Karron RA, Luke CJ, Thumar B, McMahon BA, Chen GL,
Lamirande EW, Jin H, Coelingh KL, Kemble G, Subbarao K.
Vaccine. 2011 Apr 12;29(17):3144-8. Epub 2011 Mar 4. PMID:
21377509
Attitudes and beliefs of parents concerned about vaccines: impact of timing of immunization information.
Vannice KS, Salmon DA, Shui I, Omer SB, Kissner J, Edwards KM,
Sparks R, Dekker CL, Klein NP, Gust DA.
Pediatrics. 2011 May;127 Suppl 1:S120-6. Epub 2011 Apr
18.PMID: 21502250
Page 10
Johns Hopkins Vaccine Initiative
Selected Faculty Publications and Faculty in the News
Immunization-safety monitoring systems
for the 2009 H1N1 monovalent influenza
vaccination program.
Salmon DA, Akhtar A, Mergler MJ, Vannice
KS, Izurieta H, Ball R, Lee GM, Vellozzi C,
Garman P, Cunningham F, Gellin B, Koh H,
Lurie N; H1N1 Working Group of Federal
Immunization Safety Task Force.
Pediatrics. 2011 May;127 Suppl 1:S78-86.
Epub 2011 Apr 18. Review.
PMID: 21502251
Understanding the role of human variation in vaccine adverse events: the Clinical
Immunization Safety Assessment Network.
LaRussa PS, Edwards KM, Dekker CL, Klein
NP, Halsey NA, Marchant C, Baxter R,
Engler RJ, Kissner J, Slade BA.
Pediatrics. 2011 May;127 Suppl 1:S65-73.
Epub 2011 Apr 18. PMID: 21502239
Immunization safety in US print media,
1995-2005.
Hussain H, Omer SB, Manganello JA,
Kromm EE, Carter TC, Kan L, Stokley S,
Halsey NA, Salmon DA.
Pediatrics. 2011 May;127 Suppl 1:S100-6.
Epub 2011 Apr 18. PMID: 21502237
Seroincidence of 2009 H1N1 infection in
HIV-infected and HIV-uninfected women
prior to vaccine availability.
Althoff KN, Eichelberger M, Gange SJ,
Sharp GB, Gao J, Glesby MJ, Young M,
Greenblatt RM, French AL, Villacres MC,
Minkoff H. AIDS. 2011 Jun 1;25(9):122932. PMID: 21505313
Product development partnerships hit
their stride: lessons from developing a
meningitis vaccine for Africa.
Bishai DM, Champion C, Steele ME,
Thompson L. Health Aff (Millwood). 2011
Jun;30(6):1058-64. PMID: 21653957
A dynamic landscape for antibody binding
modulates antibody-mediated neutralization of West Nile virus.
Dowd KA, Jost CA, Durbin AP, Whitehead
SS, Pierson TC. PLoS Pathog. 2011 Jun;7
(6):e1002111. Epub 2011 Jun 30.
PMID: 21738473
Smallpox virus destruction and the implications of a new vaccine.
Henderson DA.
Biosecur Bioterror. 2011 Jun;9(2):163-8.
Epub 2011 Mar 16. PMID: 21410355
Estimated economic benefits during the
'decade of vaccines' include treatment
savings, gains in labor productivity.
Stack ML, Ozawa S, Bishai DM, Mirelman
A, Tam Y, Niessen L, Walker DG, Levine
OS. Health Aff (Millwood). 2011 Jun;30
(6):1021-8. PMID: 21653952
During the 'decade of vaccines,' the lives
of 6.4 million children valued at $231 billion could be saved.
Ozawa S, Stack ML, Bishai DM, Mirelman
A, Friberg IK, Niessen L, Walker DG, Levine
OS. Health Aff (Millwood). 2011 Jun;30
(6):1010-20. PMID: 21653951
Volunteer challenge with enterotoxigenic
Escherichia coli that express intestinal
colonization factor fimbriae CS17 and
CS19.
McKenzie R, Porter CK, Cantrell JA,
Denearing B, O'Dowd A, Grahek SL, Sincock SA, Woods C, Sebeny P, Sack DA,
Tribble DR, Bourgeois AL, Savarino SJ.
J Infect Dis. 2011 Jul 1;204(1):60-4.PMID:
21628659
To contact JHVI:
Amber Bickford Cox, MPH
Program Manager, JHVI
Johns Hopkins Bloomberg School of
Public Health
Hampton House
624 N. Broadway, Room 237
Baltimore MD, 21205
email: [email protected]
phone: 410-287-4734
fax: 410-502-6898
http://www.jhsph.edu/vaccineinitiative
The epidemiologic evidence underlying
recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations.
Said MA, O'Brien KL, Nuorti JP, Singleton
R, Whitney CG, Hennessy TW.
Vaccine. 2011 Jul 26;29(33):5355-62. Epub
A call to action for the new decade of vac- 2011 Jun 12.PMID: 21664217
cines.
Moxon ER, Das P, Greenwood B, Heymann The future of immunisation policy, impleDL, Horton R, Levine OS, Plotkin S, Nossal mentation, and financing.
G. Lancet. 2011 Jul 23;378(9788):298-302. Levine OS, Bloom DE, Cherian T, de
Epub 2011 Jun 12. PMID: 21664682
Quadros C, Sow S, Wecker J, Duclos P,
Greenwood B.
Biological feasibility of measles eradicaLancet. 2011 Jul 30;378(9789):439-48.
tion.
Epub 2011 Jun 12. PMID: 21664676
Moss WJ, Strebel P.J Infect Dis. 2011
Jul;204 Suppl 1:S47-53. Review. PMID:
Detection of G3P[3] and G3P[9] rotavirus
21666201
strains in American Indian children with
evidence of gene reassortment between
Measles vaccination in HIV-infected chilhuman and animal rotaviruses.
dren: systematic review and meta-analysis Grant L, Esona M, Gentsch J, Watt J, Reid
of safety and immunogenicity.
R, Weatherholtz R, Santosham M,
Scott P, Moss WJ, Gilani Z, Low N.
Parashar U, O'Brien K.
J Infect Dis. 2011 Jul;204 Suppl 1:S164-78. J Med Virol. 2011 Jul;83(7):1288-99. doi:
Review. PMID: 21666158
10.1002/jmv.22076. PMID: 21567432
The cost-effectiveness of supplementary
immunization activities for measles: a stochastic model for Uganda.
Bishai D, Johns B, Nair D, Nabyonga-Orem
J, Fiona-Makmot B, Simons E, Dabbagh A.
J Infect Dis. 2011 Jul;204 Suppl 1:S107-15.
PMID: 21666151
Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009.
Williams SE, Klein NP, Halsey N, Dekker CL,
Baxter RP, Marchant CD, LaRussa PS,
Sparks RC, Tokars JI, Pahud BA, Aukes L,
Jakob K, Coronel S, Choi H, Slade BA, Edwards KM. Vaccine. 2011 Sep 16;29
(40):6920-7. Epub 2011 Jul 27.
PMID: 21801776
A single dose of the DENV-1 candidate
vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second
dose in a randomized trial.
Durbin AP, Whitehead SS, Shaffer D, Elwood D, Wanionek K, Thumar B, Blaney
JE, Murphy BR, Schmidt AC.
PLoS Negl Trop Dis. 2011 Aug;5(8):e1267.
Epub 2011 Aug 2. PMID: 21829748
Development and clinical evaluation of
multiple investigational monovalent DENV
vaccines to identify components for inclusion in a live attenuated tetravalent DENV
vaccine.
Durbin AP, Kirkpatrick BD, Pierce KK,
Schmidt AC, Whitehead SS.
Vaccine. 2011 Sep 23;29(42):7242-50.
Epub 2011 Jul 21. PMID: 21781997
Next-generation dengue vaccines: novel
strategies currently under development.
Durbin AP, Whitehead SS.
Viruses. 2011 Oct;3(10):1800-14. Epub
2011 Sep 26. PMID: 22069516
Comparative evaluation of the antibody in
lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays
for measuring mucosal immune responses
to Shigella antigens.
Feller AJ, McKenzie R, Taylor DN, Woods
CC, Grahek SL, Islam D, Venkatesan MM,
Hale TL, Bourgeois AL.
Vaccine. 2011 Nov 3;29(47):8487-9. Epub
2011 Sep 20. PMID: 21939714
The role of HPV in head and neck cancer
and review of the HPV vaccine.
D'Souza G, Dempsey A. Prev Med. 2011
Oct 1;53 Suppl 1:S5-S11.PMID: 21962471
Missed clinical opportunities: provider
recommendations for HPV vaccination for
11-12 year old girls are limited.
Vadaparampil ST, Kahn JA, Salmon D, Lee
JH, Quinn GP, Roetzheim R, Bruder K,
Malo TL, Proveaux T, Zhao X, Halsey N,
Giuliano AR. Vaccine. 2011 Nov 3;29
(47):8634-41. Epub 2011 Sep 14.
PMID: 21924315
Challenges to mapping the health risk of
hepatitis A virus infection.
Mohd Hanafiah K, Jacobsen KH, Wiersma
ST. Int J Health Geogr. 2011 Oct 18;10:57.
PMID: 22008459
Survey of national immunization programs
and vaccine coverage rates in Asia Pacific
countries.
Lu CY; APECI members, Santosham M.
Vaccine. 2011 Nov 7. PMID: 22075085
The cDNA-derived investigational human
parainfluenza virus type 3 vaccine rcp45 is
well tolerated, infectious, and immunoDecay and persistence of maternal dengue genic in infants and young children.
antibodies among infants in Bangkok.
Karron RA, Casey R, Thumar B, Surman S,
van Panhuis WG, Luxemburger C, Pengsaa Murphy BR, Collins PL, Schmidt AC.
K, Limkittikul K, Sabchareon A, Lang J,
Pediatr Infect Dis J. 2011 Oct;30(10):e186Durbin AP, Cummings DA.
91. PMID: 21829138
Am J Trop Med Hyg. 2011 Aug;85(2):35562. PMID: 21813859
Refinement of a human challenge model
for evaluation of enterotoxigenic EsUnderimmunization at discharge from the cherichia coli vaccines.
neonatal intensive care unit.
Harro C, Chakraborty S, Feller A, DeNearNavar-Boggan AM, Halsey NA, Escobar GJ, ing B, Cage A, Ram M, Lundgren A, SvenGolden WC, Klein NP.
nerholm AM, Bourgeois AL, Walker RI,
J Perinatol. 2011 Aug 11. doi: 10.1038/
Sack DA. Clin Vaccine Immunol. 2011
jp.2011.111. PMID: 21836550
Oct;18(10):1719-27. Epub 2011 Aug 18.
PMID: 21852546
Progress in the development of human
parainfluenza virus vaccines.
Causality assessment of serious neurologic
Schmidt AC, Schaap-Nutt A, Bartlett EJ,
adverse events following 2009 H1N1 vacSchomacker H, Boonyaratanakornkit J,
cination.
Karron RA, Collins PL. Expert Rev Respir
Williams SE, Pahud BA, Vellozzi C, DonMed. 2011 Aug;5(4):515-26.
ofrio PD, Dekker CL, Halsey N, Klein NP,
PMID: 21859271
Baxter RP, Marchant CD, Larussa PS, Barnett ED, Tokars JI, McGeeney BE, Sparks
Induction and maintenance of protective RC, Aukes LL, Jakob K, Coronel S, Sejvar JJ,
CD8+ T cells against malaria liver stages:
Slade BA, Edwards KM.
implications for vaccine development.
Vaccine. 2011 Oct 26;29(46):8302-8. Epub
Tse SW, Radtke AJ, Zavala F.
2011 Sep 3. PMID: 21893148
Mem Inst Oswaldo Cruz. 2011 Aug;106
Suppl 1:172-8. PMID: 21881772
Pneumococcal sequence type replacement among American Indian children: A
comparison of pre- and routine-PCV7 eras.
Scott JR, Hanage WP, Lipsitch M, Millar EV,
Moulton LH, Hinds J, Reid R, Santosham
M, O'Brien KL. Vaccine. 2011 Nov 14.
PMID: 22094283
Impact of More Than a Decade of Pneumococcal Conjugate Vaccine Use on Carriage and Invasive Potential in Native
American Communities.
Scott JR, Millar EV, Lipsitch M, Moulton
LH, Weatherholtz R, Perilla MJ, Jackson
DM, Beall B, Craig MJ, Reid R, Santosham
M, O'Brien KL.
J Infect Dis. 2011 Nov 29. PMID: 22128315
A Combination Vaccine Consisting of
Three Live Attenuated Enterotoxigenic
Escherichia coli Strains Expressing a Range
of Colonization Factors and Heat-Labile
Toxin Subunit B Is Well Tolerated and Immunogenic in a Placebo-Controlled Double
-Blind Phase I Trial in Healthy Adults.
Harro C, Sack D, Bourgeois AL, Walker R,
Denearing B, Feller A, Chakraborty S,
Buchwaldt C, Darsley MJ.
Clin Vaccine Immunol. 2011 Dec;18
(12):2118-27. Epub 2011 Oct 12. PMID:
21994354